Umaru Bukar, Pyriochou Anastasia, Kotsikoris Vasileios, Papapetropoulos Andreas, Topouzis Stavros
Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Rio-Patras, Greece (B.U., A.Py., V.K., S.T.); and Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece (A.Pa.).
Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Rio-Patras, Greece (B.U., A.Py., V.K., S.T.); and Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece (A.Pa.)
J Pharmacol Exp Ther. 2015 Jul;354(1):79-87. doi: 10.1124/jpet.114.222000. Epub 2015 May 14.
Intense research is conducted to identify new molecular mechanisms of angiogenesis. Previous studies have shown that the angiogenic effects of hydrogen sulfide (H2S) depend on the activation of ATP-sensitive potassium channels (KATP) and that C-type natriuretic peptide (CNP), which can act through KATP, promotes endothelial cell growth. We therefore investigated whether direct KATP activation induces angiogenic responses and whether it is required for the endothelial responses to CNP or vascular endothelial growth factor (VEGF). Chick chorioallantoic membrane (CAM) angiogenesis was similarly enhanced by the direct KATP channel activator 2-nicotinamidoethyl acetate (SG-209) and by CNP or VEGF. The KATP inhibitors glibenclamide and 5-hydroxydecanoate (5-HD) reduced basal and abolished CNP-induced CAM angiogenesis. In vitro, the direct KATP openers nicorandil and SG-209 and the polypeptides VEGF and CNP increased proliferation and migration in bEnd.3 mouse endothelial cells. In addition, VEGF and CNP induced cord-like formation on Matrigel by human umbilical vein endothelial cells (HUVECs). All these in vitro endothelial responses were effectively abrogated by glibenclamide or 5-HD. In HUVECs, a small-interfering RNA-mediated decrease in the expression of the inwardly rectifying potassium channel (Kir) 6.1 subunit impaired cell migration and network morphogenesis in response to either SG-209 or CNP. We conclude that 1) direct pharmacologic activation of KATP induces angiogenic effects in vitro and in vivo, 2) angiogenic responses to CNP and VEGF depend on KATP activation and require the expression of the Kir6.1 KATP subunit, and 3) KATP activation may underpin angiogenesis to a variety of vasoactive stimuli, including H2S, VEGF, and CNP.
人们开展了深入研究以确定血管生成的新分子机制。先前的研究表明,硫化氢(H2S)的血管生成作用取决于ATP敏感性钾通道(KATP)的激活,并且可通过KATP发挥作用的C型利钠肽(CNP)能促进内皮细胞生长。因此,我们研究了直接激活KATP是否会诱导血管生成反应,以及它是否是内皮细胞对CNP或血管内皮生长因子(VEGF)作出反应所必需的。直接激活KATP的通道激活剂2-烟酰胺基乙酸乙酯(SG-209)以及CNP或VEGF同样能增强鸡胚绒毛尿囊膜(CAM)血管生成。KATP抑制剂格列本脲和5-羟基癸酸(5-HD)可降低基础血管生成,并消除CNP诱导的CAM血管生成。在体外,直接激活KATP的药物尼可地尔和SG-209以及多肽VEGF和CNP可增加bEnd.3小鼠内皮细胞的增殖和迁移。此外,VEGF和CNP可诱导人脐静脉内皮细胞(HUVECs)在基质胶上形成索状结构。格列本脲或5-HD可有效消除所有这些体外内皮细胞反应。在HUVECs中,小干扰RNA介导的内向整流钾通道(Kir)6.1亚基表达降低会损害细胞对SG-209或CNP的迁移和网络形态发生反应。我们得出以下结论:1)直接药理激活KATP在体外和体内均可诱导血管生成效应;2)对CNP和VEGF的血管生成反应取决于KATP激活,且需要Kir6.1 KATP亚基的表达;3)KATP激活可能是多种血管活性刺激(包括H2S、VEGF和CNP)诱导血管生成的基础。